ZimVie Enters Acquisition Agreement with ARCHIMED
ZimVie Inc., a prominent player in the dental implant sector, has entered a definitive agreement to be acquired by ARCHIMED, a healthcare-focused investment firm. Under the deal, stockholders of ZimVie will receive $19.00 per share, representing a substantial premium over recent trading averages, which stands at approximately 99% above the 90-day volume-weighted average price.
Details of the Acquisition Agreement
This strategic move comes as ZimVie seeks to enhance its growth trajectory and bring advanced dental technologies to a broader audience. The acquisition is expected to solidify ZimVie's market position and provide the necessary resources for innovation and expansion.
The total enterprise value of the transaction is approximately $730 million, reflecting both ZimVie's operational success and potential for future growth. CEO Vafa Jamali expressed optimism about the partnership, highlighting the value the team has built over recent years.
Reaction from Leadership
André-Michel Ballester, Managing Partner at ARCHIMED, shared his excitement for collaborating with ZimVie. He noted the company’s robust fundamentals and strong growth potential, indicating that ARCHIMED plans to support ZimVie through its next developmental phase.
Regulatory Approvals and Closing Timeline
The acquisition has garnered unanimous approval from ZimVie's Board of Directors and is projected to conclude by year-end 2025, contingent on meeting customary closing conditions. This will include necessary approvals from ZimVie’s stockholders and relevant regulatory entities. Until the completion of this agreement, ZimVie will continue its operations independently.
Go-Shop Period for Alternative Proposals
In a proactive move, ZimVie will engage in a 40-day 'go-shop' period where it can seek alternative proposals from other potential buyers. This phase is aimed at ensuring that ZimVie receives the best possible offer while still under the aegis of ARCHIMED's proposal.
About ZimVie
ZimVie is actively engaged in developing and supplying a broad spectrum of dental implant solutions to facilitate effective tooth replacement and restoration. With roots in Palm Beach Gardens and operations worldwide, ZimVie is dedicated to enriching patient experiences through its innovative products.
About ARCHIMED
ARCHIMED is a prominent investment firm with a dedicated focus on healthcare. Its diverse portfolio includes significant contributions to various healthcare sectors, demonstrating its commitment to operational excellence and sustainable growth. With a managed capital of around €8 billion, ARCHIMED combines financial acumen with deep industry expertise to foster the advancement of healthcare businesses.
Frequently Asked Questions
What is the price per share being offered in the acquisition?
The acquisition offer is set at $19.00 per share.
Who is acquiring ZimVie?
ZimVie is being acquired by ARCHIMED, an investment firm specializing in healthcare.
What is the total enterprise value of the acquisition?
The total enterprise value of the transaction is approximately $730 million.
When is the acquisition expected to close?
The acquisition is expected to be finalized by year-end 2025.
Will ZimVie continue to operate independently until the acquisition is complete?
Yes, ZimVie will maintain its operations independently until the acquisition is finalized.
